220,657 results on '"Hepatocellular carcinoma"'
Search Results
102. Serum CYFRA 21-1 and CK19-2G2 as Predictive Biomarkers of Response to Transarterial Chemoembolization in Hepatitis C–related Hepatocellular Carcinoma Among Egyptians: A Prospective Study
103. Liver Resection for Hepatocellular Carcinoma: Recent Advances
104. Assessing the Predictive Accuracy of the aMAP Risk Score for Hepatocellular Carcinoma (HCC): Diagnostic Test Accuracy and Meta-analysis
105. Bioinformatics in vivo and in vitro assays identified miR-486-5p as a tumor suppressor miRNA in hepatocellular carcinoma
106. -RAMP3 promotes hepatocellular carcinoma tumor cell-mediated CCL2 degradation by supporting membrane distribution of ACKR2
107. IGFALS suppresses hepatocellular carcinoma progression by stabilizing PPAR-γ
108. Risk of transplant rejection associated with ICIs prior to liver transplantation in HCC: A multicenter retrospective study
109. Single-cell transcriptomics reveals tumor microenvironment changes and prognostic gene signatures in hepatocellular carcinoma
110. Carbonic anhydrase 2 facilitates sorafenib resistance by counteracting MCT4-mediated intracellular pH dysregulation in HCC
111. The cellular senescence score (CSS) is a comprehensive biomarker to predict prognosis and assess senescence and immune characteristics in hepatocellular carcinoma (HCC)
112. Establishment of prognostic risk model related to disulfidptosis and immune infiltration in hepatocellular carcinoma
113. Insights into the accumulation and hepatobiliary transport of bisphenols (BPs) in liver and bile
114. Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma
115. Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy
116. New strategy of LI-RADS v2018 to improve the sensitivity for small hepatocellular carcinoma ≤ 3.0 cm on extracellular-contrast enhanced MRI
117. Prediction of PD-L1 expression in unresectable hepatocellular carcinoma with gadoxetic acid-enhanced MRI
118. Idarubicin-loaded degradable hydrogel for TACE therapy enhances anti-tumor immunity in hepatocellular carcinoma
119. 99mTc/90Y radiolabeled biodegradable gel microspheres for lung shutting fraction assessment and radioembolization in hepatocellular carcinoma theranostics
120. Chrysin exacerbates mitophagy-mediated pyroptosis to inhibit the proliferation of hepatocellular carcinoma cells by targeting p53
121. Screening of Cancer-Specific Biomarkers for Hepatitis B-Related Hepatocellular Carcinoma Based on a Proteome Microarray
122. Elucidation of molecular mechanisms, pathways, and diseases modulated by arsenicals through toxogenomics and multi-omics analysis
123. Evaluating the potential of off-the-shelf engineered mesenchymal stem cells for targeted Hepatocellular Carcinoma treatment: A multisite proof-of-concept study
124. Unravelling the role of natural and synthetic products as DNA topoisomerase inhibitors in hepatocellular carcinoma
125. Design, synthesis, molecular docking, and evaluation of sulfonyl quinazoline analogues as promising liver cancer drugs
126. Epidemiological, diagnostic, therapeutic and prognostic impact of hepatitis B and D virus infection on hepatocellular carcinoma: A review of the literature
127. Up-front resection for hepatocellular carcinoma: Assessing futility in the preoperative setting
128. Neoadjuvant therapy with triple therapy for centrally located hepatocellular carcinoma
129. Prognostic Value of the ASAP Score for Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma: A Multicenter Analysis of 1,239 Patients
130. Hepatocellular carcinoma recognition from ultrasound images with pixelated disparity based deep CNN based fire hawk optimizer
131. MMP-9-responsive probe for fluorescence-magnetic resonance dual-mode imaging of hepatocellular carcinoma models with different metastatic capacities
132. Machine learning and molecular subtyping reveal the impact of diverse patterns of cell death on the prognosis and treatment of hepatocellular carcinoma
133. Automated ultrasonography of hepatocellular carcinoma using discrete wavelet transform based deep-learning neural network
134. Targeting microRNA methylation: Innovative approaches to diagnosing and treating hepatocellular carcinoma
135. Tumor vascular occlusion by calcium-based thermosensitizer provokes continuous cavitation effect and thermal energy transition efficiency of radiofrequency ablation therapy
136. Serum Galectin-9 mirrors immune-evasive microenvironment and predicts early recurrence in hepatocellular carcinoma
137. Novel oncogenes and tumor suppressor genes in Hepatocellular Carcinoma: Carcinogenesis, progression, and therapeutic targets
138. Optimizing interventional therapy: A homogeneous lipiodol formulation of Tirapazamine and Sorafenib responsive to post-embolization microenvironment
139. Prediction of treatment response and outcome of transarterial chemoembolization in patients with hepatocellular carcinoma using artificial intelligence: A systematic review of efficacy
140. Imaging-based prediction of early recurrence and neoadjuvant therapy outcomes for resectable beyond Milan HCC
141. TRIM29 reverses lenvatinib resistance in liver cancer cells by ubiquitinating and degrading YBX1 to inhibit the PI3K/AKT pathway
142. LCAT deficiency promotes hepatocellular carcinoma progression and lenvatinib resistance by promoting triglyceride catabolism and fatty acid oxidation
143. Formosanin C induces autophagy-mediated cell death in hepatocellular carcinoma through activating DUSP1/AMPK/ULK1/Beclin1 signaling pathway
144. The multifaceted roles of macrophages in the transition from hepatitis to hepatocellular carcinoma: From mechanisms to therapeutic strategies
145. Peroxynitrite is involved in the mitochondrial dysfunction induced by Sorafenib in liver cancer cells
146. STAT3 orchestrates immune dynamics in hepatocellular carcinoma: A pivotal nexus in tumor progression
147. circCCNY enhances lenvatinib sensitivity and suppresses immune evasion in hepatocellular carcinoma by serving as a scaffold for SMURF1 mediated HSP60 degradation
148. A high throughput assay for phosphoribosylformylglycinamidine synthase
149. The Clinical Utility of Liver-Specific Ultrasound Contrast Agents During Hepatocellular Carcinoma Imaging
150. The distinct characteristic of two peritoneal macrophage subsets in a mouse model of hepatocellular carcinoma presents a novel therapeutic strategy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.